Related Experiment Video
Updated: Jan 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[New Potential Therapies for Chronic Hepatitis B].
Sun Hong Yoo1, Jung Hyun Kwon1
1Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Hepatitis B virus (HBV) infection can lead to liver cirrhosis and cancer. Emerging therapies aim for HBV cure, going beyond current treatments that inhibit replication but rarely clear the virus.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic Hepatitis B virus (HBV) infection causes persistent liver inflammation.
- Long-term inflammation is a key factor in developing liver cirrhosis and hepatocellular carcinoma.
- Current treatments like nucleos(t)ide analogues and pegylated interferon inhibit HBV replication but seldom achieve HBsAg clearance.
Purpose of the Study:
- To introduce a novel definition for Hepatitis B virus (HBV) cure.
- To review emerging therapeutic strategies for achieving HBV cure.
- To discuss the potential of direct-acting antivirals and immunomodulatory agents.
Main Methods:
- Literature review of recent advancements in HBV treatment.
- Analysis of emerging therapeutic classes including direct-acting antivirals.
- Evaluation of immunomodulatory antivirals for HBV cure.
Main Results:
- Current therapies are limited in achieving complete viral clearance (HBsAg loss).
- New therapeutic agents show promise in addressing limitations of existing treatments.
- Emerging direct-acting and immune-modulating therapies are being investigated for HBV cure.
Conclusions:
- A new definition of HBV cure is proposed to guide future research.
- Emerging therapies offer potential for achieving functional or complete HBV cure.
- Further investigation into direct-acting and immune-modulatory antivirals is warranted.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Microorganisms in Medicine and Therapeutics
Retrovirus Life Cycles
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...